Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
- Resource Type
- Article
- Source
- Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p340-340, 185p
- Subject
- Language
- ISSN
- 0732183X